What question did this study set out to answer?

To determine if augmenting erythropoiesis with recombinant human erythropoietin (rEPO) at sea level alters the erythropoietic response during high altitude acclimatization.

March 10, 2026Open Access

Augmenting erythropoiesis using recombinant human erythropoietin at sea level blunts the high altitude induced increase in erythropoiesis

Puntos clave

To determine if augmenting erythropoiesis with recombinant human erythropoietin (rEPO) at sea level alters the erythropoietic response during high altitude acclimatization.
Conducted sea level testing and a 4-week intervention with rEPO or placebo
Monitored erythropoiesis through blood samples before and after intervention
Exposed participants to high altitude for 15 days and assessed Hb mass afterwards
rEPO augmented haemoglobin mass at sea level by 88 g compared to placebo
At high altitude, rEPO group had increased hemoglobin concentration and arterial oxygen content
Despite higher hemoglobin levels, rEPO group exhibited lower EPO levels and reticulocyte counts at high altitude
No significant difference in haemoglobin mass was observed between rEPO and placebo groups post-high altitude exposure

Resumen

Abstract Erythropoiesis increases with high altitude (HA) acclimatization. Recombinant human erythropoietin (rEPO) induces erythropoiesis. However, it is unknown whether pharmacologically augmenting erythropoiesis with rEPO at sea level alters the erythropoietic response during subsequent HA acclimatization. We aimed to determine whether augmenting erythropoiesis with rEPO blunts the erythropoietic response during HA acclimatization. Twenty healthy participants completed sea level testing, a 4‐week intervention at sea level with rEPO ( n = 9; 2 females) or placebo (PL; n = 11; 3 females), 15‐day HA exposure (4300 m), and testing the day after returning from high altitude (PostHA). Blood samples were collected throughout the study and haemoglobin mass (Hb mass ) was assessed before and after the sea level intervention and PostHA. As expected, at sea level, rEPO augmented Hb mass (rEPO‐PL mean diff: 88 g, 95% CI: 45.6 g, 130.6 g). At HA, the rEPO group had higher Hb, which augmented arterial oxygen content (mean diff. = 1.93 mL O 2 dL −1 , 95% CI: 0.59 mL O 2 dL −1 , 3.27 mL O 2 dL −1 ). Despite similar oxygen saturation, the rEPO group had lower EPO (∼7 mlU mL −1 ) and reticulocyte count (∼1 percentage units) compared to PL group at HA. Hb mass at PostHA was not different between rEPO ( n = 5) and PL group (mean diff.: 35 g, 95% CI: −10.99 g, 81.02 g), which confirmed blunted erythropoiesis at HA. The present study demonstrates that pharmacologically augmenting erythropoiesis with rEPO at sea level blunts the HA induced increase in erythropoiesis. image Key points Erythropoiesis increases with high altitude (HA) acclimatization. Recombinant human erythropoietin (rEPO) stimulates erythropoiesis at sea level, but it is unknown whether pharmacologically augmenting erythropoiesis with rEPO alters erythropoietic response during subsequent HA acclimatization. We assessed erythropoiesis before and after a 4‐week intervention of rEPO or placebo and after 15 days at 4300 m. Compared to placebo, rEPO augmented erythropoiesis at sea level but markedly attenuated the erythropoietic response to HA acclimatization. Our data indicate that pharmacologically augmenting erythropoiesis with rEPO at sea level blunts the HA induced increase in erythropoiesis.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo